Abstract
It has been a conventional notion that cytoplasmic recombinant expression leads to either soluble protein or inclusion bodies. In the latter case, it was always assumed that proteins in inclusion bodies (IBs) are more or less unfolded and hence require complete denaturing condition for solubilization, which uses strong detergents, urea or guanidine hydrochloride. However, we often observe distribution of expressed proteins in both soluble and insoluble fractions. In such expression, IBs are often loose and of flocculate morphology. We believe that such distribution is due to association of near native structures of the expressed proteins, which cause either aggregation into insoluble fractions or unstable soluble proteins. In our experience, although not reported by others, interleukin-1α, interferon-γ, tumor necrosis factors, fibroblast growth factors, His-tagged fyn kinase and many other proteins showed such behavior. If this occurs, we have experienced problems of instability, low yield and insolubility whether purification is done from the soluble fraction or by refolding of IBs. Arginine has shown great promise in non-denaturaing solubilization of some of these proteins we have tested.
Keywords: Non-denaturing solubilization, inclusion bodies, arginine, GFP, FGF-20
Current Pharmaceutical Biotechnology
Title: Non-Denaturing Solubilization of Inclusion Bodies
Volume: 11 Issue: 3
Author(s): Kouhei Tsumoto, Ryota Abe, Daisuke Ejima and Tsutomu Arakawa
Affiliation:
Keywords: Non-denaturing solubilization, inclusion bodies, arginine, GFP, FGF-20
Abstract: It has been a conventional notion that cytoplasmic recombinant expression leads to either soluble protein or inclusion bodies. In the latter case, it was always assumed that proteins in inclusion bodies (IBs) are more or less unfolded and hence require complete denaturing condition for solubilization, which uses strong detergents, urea or guanidine hydrochloride. However, we often observe distribution of expressed proteins in both soluble and insoluble fractions. In such expression, IBs are often loose and of flocculate morphology. We believe that such distribution is due to association of near native structures of the expressed proteins, which cause either aggregation into insoluble fractions or unstable soluble proteins. In our experience, although not reported by others, interleukin-1α, interferon-γ, tumor necrosis factors, fibroblast growth factors, His-tagged fyn kinase and many other proteins showed such behavior. If this occurs, we have experienced problems of instability, low yield and insolubility whether purification is done from the soluble fraction or by refolding of IBs. Arginine has shown great promise in non-denaturaing solubilization of some of these proteins we have tested.
Export Options
About this article
Cite this article as:
Tsumoto Kouhei, Abe Ryota, Ejima Daisuke and Arakawa Tsutomu, Non-Denaturing Solubilization of Inclusion Bodies, Current Pharmaceutical Biotechnology 2010; 11 (3) . https://dx.doi.org/10.2174/138920110791111924
DOI https://dx.doi.org/10.2174/138920110791111924 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Lymphoma and the Control of B Cell Growth and Differentiation
Current Molecular Medicine Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death
Current Topics in Medicinal Chemistry TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Synthesis and Biological Activity of New Tricyclic Purine Derivatives Obtained by Intramolecular N-7 Alkylation
Letters in Drug Design & Discovery Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development
Current Drug Research Reviews Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews The Concept of Protein Mosaics: Physiological Role and Relevance for Prion Disease
Current Proteomics Editorial [ Murine Atherosclerosis (Part III) Guest Editor: Godfrey S. Getz ]
Current Drug Targets Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics GnRH-Analogues for Ovarian Protection in Childhood Cancer Patients: How Adult Hypotheses are Relevant in Prepubertal Females
Current Drug Targets Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry GSK3 at the Edge: Regulation of Developmental Specification and Cell Polarization
Current Drug Targets Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets